![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca Licenses Vanderbilt University’s Monoclonal Antibodies for COVID-19
AstraZeneca Licenses Vanderbilt University’s Monoclonal Antibodies for COVID-19
![AstraZeneca](https://www.fdanews.com/ext/resources/test/Device_Images2/AstraZeneca.gif?t=1576126438&width=430)
AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19.
Monoclonal antibodies are synthesized versions of natural antibodies that may be able to neutralize the SARS-CoV-2 virus.
The company said it plans to begin a study of two antibodies as a combination treatment within the next two months.
Upcoming Events
-
21Oct